Multi-target Inhibitor Combined With Cytotoxic Treatment Of Malignant Glioma Efficacy Of Experimental Study

Objective Multi-target inhibitor vandetanib combined cytotoxic drugs carmustin(BCNU) on the proliferation and invasion of C6rat glioma.Methods Subculture c6rat glioma cells, the impact of drugs on cell viability using the MTT assay, HE staining observed changes in cell morphology. In situ injection of C6rat glioma model, six days into the vandetanib group (50mg/kg. d), BCNU group (25mg/kg. d), the combination group (vandetanib+BCNU) and control groups, the next administration, two weeks after the decapitation method put to death in rat brain, do the tumor tissue sections to calculate the size of the tumor volume, immunohistochemical SP method was used to mark groups of tumor vascular endothelial cells todetect transplanted tumor microvessel density (MVD), to detect the expression of MMP1protein related to tumor invasiveness. Groups of apoptotic index by TUNEL method.Results Suppression and promote the apoptotic effect on tumor cells, the combination group were significantly higher than the BCNU group (P<0.01). Compared with the control group, the group of BCNU tumor volumes decreased by34.0%(P<0.05), xenografts MMP1expression as (++), MVD was no significant change,62.6%of the rate of apoptosis of transplanted tumor cells (P<0.05); combination group tumor volumes decreased by56.0%(P<0.05), xenografts MMP1expression positive (+), MVD was reduced53%(P<0.05). apoptosis rate of82.0%(P<0.05);Conclusion The combination therapy can not only significantly inhibit the c6glioma cell tumor growth but also reduce tumor invasion, and to provide experimental basis for the joint multi-target inhibitors and cytotoxic drugs in clinical treatment of malignant glioma.